Personalized Cancer Vaccine Summit

With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.

The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston for the third year bringing together the top industry players developing individualized approaches across several modalities including mRNA, DNA, peptides, viral, dendritic cell and more to share how they are conquering common challenges, developing novel bioinformatic strategies, and achieving clinical efficacy.

Join the likes of BioNTech, CureVac, Imvax, NousCom and 80+ key stakeholders at the ultimate learning and networking forum to help you and your teams advance your patient-centric pipelines towards the clinic and regulatory approval.

URLs:
Website: https://go.evvnt.com/2558274-0?pid=176 
Tickets: https://go.evvnt.com/2558274-2?pid=176 
Brochure: https://go.evvnt.com/2558274-3?pid=176 

Time: 8:00 AM - 5:00 PM

Prices:
Conference + Focus Day - Industry Pricing: USD 4197.00,
Conference Only - Industry Pricing: USD 2999.00,
Conference + Focus Day - Academic Pricing: USD 3597.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + Focus Day - Solution Provider Pricing: USD 5097.00,
Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, Elisa Scarselli, Chief Scientific Officer, Nouscom, Éric Halioua, President and Chief Executive Officer, PDC*line Pharma, Hans Keirstead, Chief Executive Officer, AiVita Biomedical, Heinz Lubenau, Chief Executive Officer, NEC Bio Therapeutics, Keith Knutson, Professor of Immunology, Mayo Clinic, Mark Exley, Chief Scientific Officer, Imvax, Ming Li, Professor, University of Waterloo School of Pharmacy, Moutih Rafei, Chief Scientific Officer, Defence Therapeutics, Myriam Mendila, Chief Scientific Officer and Head of Research and Development, CureVacSE, Niranjan Y. Sardesai, Chief Executive Officer, Geneos Therapeutics, Philip Arlen, President and Chief Executive Officer, Precision Biologics, Prasun Chakraborty, Founder and Chief Executive Officer, Genevation, Richard Klemke, Founder and Chief Scientific Officer, Cytonus Therapeutics, Roy de Souza, Chief Executive Officer and Co-Founder, BreakBio, Ruben Rizzi, Senior Vice President - Global Regulatory Affairs, BioNTech AG, Sergio Quezada, Chief Scientific Officer, Achilles Therapeutics, William Jia, Chief Scientific Officer, Virogin Biotech, Wilson McKerrow, Principal Data Scientist, ROME Therapeutics, Yan Asmann, Associate Professor of BioMedical Informatics, Mayo Clinic